Introduction
Although a high response rate is achieved in patients with multiple myeloma (MM) by high dose chemotherapy, the management of MM patients remains a problem.
Complementary therapeutics are needed to cure or control the disease. The idiotype (Id) of the myeloma immunoglobulin (Ig) is regarded a tumor specific antigen and a target for immunotherapy.
Natural occurring MHC restricted myeloma Id-specific T-cells have been identified. 1 Such T-cells may target Id Ig peptide/MHC complexes on myeloma cells and might lyse tumor cells. 2, 3 Idiotype vaccination may therefore be a treatment approach to induce a therapeutic idiotype specific T cell response. 2, 3, 4 The concept of idiotype immunization in multiple myeloma was already introduced about 30 years ago. 5 The idiotype seems however to be a weak immunogen and to evoke a strong response adjuvant cytokines should be added. GM-CSF augments the functional capacity of antigen presenting cells and IL-12 amplifies the immune response and directs towards a type I T cell response. 4 A Th 1 type cellular response seems to be of importance for tumor regression, while a Th 2 T cell response might provide a microenvironment conducive to disease progression. 6 Idiotype vaccination in malignant lymphomas induced idiotype specific T cells and complete blood molecular remission. 7 In MM, idiotype vaccination evoked an idiotype specific T cell response and occasionally clinical effects as reduction of serum M-component and disease stabilisation. 8 The clonal cell compartment in myeloma represents an ongoing differentiating cell population 9 including pre-switch cells. 10, 11 The number of pre-plasma cells seems to In this study, we monitored peripheral blood (PB) tumor cells by a real-time allelespecific oligonucleotides (ASO) PCR method in myeloma patients undergoing Id vaccination and could show that immunization, using the autologous myeloma Id, induced PB tumor mass reduction.
Materials and methods
Patients with multiple myeloma stage I and an increasing serum M-component concentration were included. Ten patients were considered for the study. In 6/10 patients we were able to monitor the level of clonal cells using complementarity determining region 3 (CDR3) specific PCR assays, which 6 patients are included in this report.
The M-component was purified as described. 4 The patients were immunized with the autologous Id together with IL-12 with or without GM-CSF as follows: i) in the IL-12/GM-CSF group 0. the plates were washed twice in PBS. Subsequently, 100 µl aliquots of freshly prepared PBMC (10 6 cells/ml) were added to each well. Cells were incubated with F(ab') 2 -fragments of the autologous or isotypic monoclonal IgG (1 pg/ml -100 µg/ml) for 30 h.
To visualize spots corresponding to single -IFN secreting cells, the cells were washed with PBS and the wells were incubated with a rabbit monoclonal anti-human -IFN at 37°C for 2 h. After washing, biotinylated anti-rabbit IgG (Vector Lab, Burlington, CA, USA) was added, followed by avidin-biotin-peroxidase complex (ABC, Vectastin elite kit, Vector Lab) for 50 min. After peroxidase staining using the substrate 3-amino-9-ethyl-carbasol (Sigma St Louis., MA, USA), the number of spots corresponding to cells secreting -IFN was quantified using an automatic device (Zeiss-Kantron, Jena, For the generation of ASO primers and probes, the V H gene sequence was determined by RT-PCR using consensus V H family primers. 13 Patient-specific quantitative real-time PCR analyses were performed as previously described. 14 
Results and Discussion
For the development of an idiotype vaccination strategy in MM patients we are focusing on stage I based on the observation that early stage MM patients may naturally exhibit mainly type I Id-specific T cells whereas in late stage type II Id-specific T cells seemed to prevail. 1 In the present study, half of the patients had an idiotype specific proliferative T cell response pre-vaccination, which is in agreement with our earlier observations. 15 In stage I, the general T cell functions also seems to be well preserved (data to be published).
In 8/10 of the stage I patients considered for the study, we were able to identify the myeloma specific immunoglobulin heavy chain gene (IgH) DNA sequence. For these 8 patients we designed a patient-specific ASO primer and a patient-specific dual-labeled fluorogenic probe (ASO TaqMan probe) corresponding to CDR3 (Table 1) . The CDR3 primers were tested on a panel of DNA from different patients, ensuring that the primers For personal use only. on October 17, 2017. by guest www.bloodjournal.org From amplified only an IgH sequence from the patient of interest. The forward CDR3 primer was designed to span the V-D junction, and the CDR3 TaqMan probe was designed to span the D-J junction giving maximum specificity (Table 1) . For
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One patient (MM-5) achieved a complete peripheral blood molecular remission (below 1:10 6 , PCR negative using both ASO real-time and nested RT-PCR). Three patients had a reduction of 92%, 79% and 54% respectively of the clonotypic B cells (MM-1,3 and 2 respectively). Two patients (MM-4 and 6) had unchanged levels of clonal B cells. In no patient a significant change of the serum M-component concentration was observed during the study period ( Table 2 ). (Table 2) . Thus, 3 patients mounting an idiotype specific T cell response had tumor cell reduction while one patient developing an anti-idiotypic cellular response showed no decrease in circulating tumor B cells. However, one patient (MM-3) had a tumor mass reduction without a detectable T cell response. A similar phenomen has been described in melanoma patients immunized with MAGE-3 peptides. Partial and complete remissions were obtained without detectable MAGE-3 specific T cells. 16 Massaia and co-workers 17 malignancies. However, in our patients no major tumor reduction was noted, as measured by serum M-component conc., which was stable over time in all patients, indicating that myeloma specific T cells might only be able to eradicate a minimal tumor burden. This is 19 .
In conclusion, Id vaccination in MM patients may induce tumor specific T cells which might target circulating clonal tumor B cells. Idiotype vaccination may preferentially be applied when the tumor load is low, i.e. early during the course of the disease or after chemotherapy. In the latter case measures should be taken to augment T cell functions as otherwise an effective tumor specific immune response may not be induced.
